Hikal Limited, commonly referred to as Hikal, is a prominent player in the pharmaceutical preparation manufacturing industry, with its headquarters based in India. Established in 1988, the company has grown to serve a diverse global client base, primarily across North America, Europe, and Asia. Hikal specialises in the development and manufacturing of active pharmaceutical ingredients (APIs), intermediates, and custom synthesis services, recognised for their high quality and compliance with international standards.
With a strong focus on innovation and regulatory excellence, Hikal has earned a notable reputation within the pharmaceutical sector. Its strategic milestones include expanding its manufacturing capabilities and establishing a robust presence in the global pharmaceutical supply chain. As a key industry participant, Hikal continues to advance its offerings, supporting the development of life-saving medicines worldwide.
-9 vs industry average
Hikal’s score of 29 is lower than 44% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Hikal?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2027
Reported emissions
Scope 3 accounts for ••• of total emissions.
Hikal's reported carbon emissions
In 2024, Hikal reported Scope 1 emissions of approximately 21,410,710 kg CO2e and Scope 2 emissions of approximately 67,287,010 kg CO2e. For 2023, the company reported Scope 1 emissions of approximately 26,793,240 kg CO2e and Scope 2 emissions of approximately 67,737,300 kg CO2e. In 2022, Hikal reported Scope 1 emissions of approximately 57,457,000 kg CO2e.
Hikal is committed to a significant decarbonisation initiative, aiming for a 30% reduction in Scope 1 and 2 emissions by 2027-28, using 2022-23 as a baseline. This target is detailed in their sustainability reporting.
As a pharmaceutical preparation manufacturing company based in India, Hikal operates within an industry increasingly focused on environmental stewardship and climate action. The company has not disclosed Scope 3 emissions data for the reporting periods.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Hikal’s Climate Goals (2030 & 2050)
2 goals2028
30% reduction in Scope 1
We have embarked on an ambitious decarbonisation journey, firmly aligned with our commitment to achieve a 30% reduction in Scope 1 and 2 emi…
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 2 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Hikal
Frequently asked questions
Common questions about Hikal’s sustainability data and climate commitments
Data year: 2024
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project